Factor XI antibodies REGN7508 and REGN9933 after leg artery procedures in peripheral artery disease
Tests REGN7508 and REGN9933 against rivaroxaban or placebo in peripheral artery disease after leg revascularization.
Key facts
- Who runs it
- Regeneron Pharmaceuticals
- Where
- Alexander City, Amarillo, Avondale, Charlotte, Crystal River, Cypress, DeSoto, Flemington, Fort Wayne, Hammond, Jackson, Jacksonville, Knoxville, Little Rock, Los Angeles, Miami Lakes, Mooresville, Munster, Oklahoma City, Oxnard, Panama City, Petal, Plano, Rapid City, Shreveport, Tampa, Tullahoma, Valhalla, and West Hills, United StatesSee the 30 sitesAlso in 20 other countries, 96 sites
- Trial code
- Registry title
- Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 7,050 people, planned
- Started
- 10 Jul 2026
- Expected to end
- 16 Nov 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- REGN7508
- REGN9933
- Placebo
- Rivaroxaban
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with peripheral artery disease (narrowed blood vessels in the limbs) who recently had a procedure to improve blood flow in the legs.
- Age
- 18 Years and older.
- Sex
- All sexes can join.
- Disease stage
- Symptomatic peripheral artery disease caused by hardened, narrowed arteries (atherosclerosis). A successful procedure to restore leg blood flow, below the external iliac artery, within 10 days before joining. At least 1 extra risk factor is needed: bypass with an artificial graft, a stent, a treated narrowing longer than 15 cm (5.9 in), an earlier leg procedure or amputation for PAD, type 2 diabetes treated with medicine, symptomatic heart artery disease, chronic kidney disease, or age 75 years or more.
- Earlier treatment
- A successful lower leg blood flow procedure (LER) within 10 days before joining is required. People with a recent heart artery procedure cannot join.
Main reasons for not taking part
- A condition needing long-term blood thinner treatment, including known triple positive antiphospholipid syndrome.
- A known bleeding disorder, platelet count <50,000/mm^3, or past brain bleeding not caused by injury.
- Known cerebral amyloid angiopathy or unrepaired blood vessel malformations in the brain.
- Cohort 2 only: eGFR <15 mL/min/1.73m^2, on dialysis, or expected to start dialysis within 12 weeks.
- Allergy or other reason not to take REGN7508, REGN9933, or rivaroxaban (Cohort 2 only).
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Successful LER distal to the external iliac artery for ischemia due to atherosclerotic disease within 10 days prior to randomization as described in the protocol
- At least 1 of the following enrichment factors for major thrombotic vascular events:; Bypass with prosthetic graft; Endovascular treatment with stenting; Target lesion length >15 cm; History of LER or amputation for PAD prior to qualifying LER; Type 2 diabetes mellitus requiring pharmacologic treatment; Comorbid symptomatic coronary artery disease as described in the protocol; Chronic kidney disease as described in the protocol; Age ≥75 years
Who cannot take part
- Has any active clinical condition requiring chronic therapeutic anticoagulation after the index revascularization including known triple positive antiphospholipid syndrome
- Has any other condition or therapy which would make the participant unsuitable for this study or not allow participation for the full planned study period
- Has allergy, hypersensitivity, or other contraindication to REGN7508, REGN9933, or rivaroxaban (Cohort 2 only) or their excipients; Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
- Has known bleeding diathesis, platelet count <50,000/mm\^3 or history of non-traumatic intracerebral hemorrhage, known cerebral amyloid angiopathy, or known unrepaired cerebrovascular malformations
- For Cohort 2 only: Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m\^2 within 14 days prior to randomization or on dialysis or expected to be started on dialysis within the next 12 weeks starting from randomization
- Has recent coronary revascularization as described in the protocol
Where in United States
Also in 20 other countries, 96 sites
- Advanced CardiovascularAlexander City, United StatesContact: Clinical Trials AdministratorTaking people
- Lake Martin Medical and Vascular CenterAlexander City, United StatesContact: Clinical Trials AdministratorTaking people
- PharmaTex ResearchAmarillo, United StatesContact: Clinical Trials AdministratorTaking people
- Axsendo Clinical Research, Integrated Medical ServicesAvondale, United StatesContact: Clinical Trials AdministratorTaking people
- Mecklenburg Heart Specialists Vascular Institute and Vein CenterCharlotte, United StatesContact: Clinical Trials AdministratorTaking people
- Nature Coast Clinical Research - CardiologyCrystal River, United StatesContact: Clinical Trials AdministratorTaking people
- Vital Heart and VeinCypress, United StatesContact: Clinical Trials AdministratorTaking people
- Epic Medical ResearchDeSoto, United StatesContact: Clinical Trials AdministratorTaking people
- Advanced Heart and Vascular Institute of HunterdonFlemington, United StatesContact: Clinical Trials AdministratorTaking people
- Lutheran Medical Group LLC dba Lutheran Health PhysiciansFort Wayne, United StatesContact: Clinical Trials AdministratorTaking people
- ASHA Clinical Research-Munster, LLCHammond, United StatesContact: Clinical Trials AdministratorTaking people
- Apex Research Foundation, LLCJackson, United StatesContact: Clinical Trials AdministratorTaking people
- University of Florida (UF) Health Jacksonville Clinical CenterJacksonville, United StatesContact: Clinical Trials AdministratorTaking people
- Tennova TCMCKnoxville, United StatesContact: Clinical Trials AdministratorTaking people
- Applied Research Center of ArkansasLittle Rock, United StatesContact: Clinical Trials AdministratorTaking people
- Angel City Research, Inc.Los Angeles, United StatesContact: Clinical Trials AdministratorTaking people
- Inpatient Research Clinic LLCMiami Lakes, United StatesContact: Clinical Trials AdministratorTaking people
- Accellacare of Piedmont, Piedmont HealthcareMooresville, United StatesContact: Clinical Trials AdministratorTaking people
- Profound Research, Powers Health Medical GroupMunster, United StatesContact: Clinical Trials AdministratorTaking people
- Hightower ClinicalOklahoma City, United StatesContact: Clinical Trials AdministratorTaking people
- Pacific Cardiovascular and Vein InstituteOxnard, United StatesContact: Clinical Trials AdministratorTaking people
- Cardiovascular Institute of Northwest Florida, Main OfficePanama City, United StatesContact: Clinical Trials AdministratorTaking people
- Rovia Clinical Research - Hattiesburg ClinicPetal, United StatesContact: Clinical Trials AdministratorTaking people
- Epic Medical Research - PlanoPlano, United StatesContact: Clinical Trials AdministratorTaking people
- Monument Health Clinical ResearchRapid City, United StatesContact: Clinical Trials AdministratorTaking people
- Cardiovascular SolutionsShreveport, United StatesContact: Clinical Trials AdministratorTaking people
- Tampa Cardiovascular Interventions and ResearchTampa, United StatesContact: Clinical Trials AdministratorTaking people
- Vanderbilt Heart and Vascular Tullahoma, Cardiology and Vascular AssociatesTullahoma, United StatesContact: Clinical Trials AdministratorTaking people
- Westchester Medical CenterValhalla, United StatesContact: Clinical Trials AdministratorTaking people
- Interventional Cardiology Medical GroupWest Hills, United StatesContact: Clinical Trials AdministratorTaking people
About the trial
What the trial wants to find out
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet.
Read full original descriptionShow less
The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo.
The study is looking at several other research questions, including:
* What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally
The 2 groups in the trial
- Cohort 1Treatment being tested
Treatment: REGN7508, REGN9933, and Placebo
- Cohort 2Treatment being tested
Treatment: REGN7508, REGN9933, and Rivaroxaban
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants With Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
- Plain-language title
- Factor XI antibodies REGN7508 and REGN9933 after leg artery procedures in peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 5 November 2026